BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, Scorilas A, Klinakis A. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Rep 2019;20:e46821. [PMID: 30665945 DOI: 10.15252/embr.201846821] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Oleksiewicz U, Machnik M. Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. Semin Cancer Biol 2020:S1044-579X(20)30274-1. [PMID: 33359485 DOI: 10.1016/j.semcancer.2020.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med 2021;10:2216-31. [PMID: 33655698 DOI: 10.1002/cam4.3649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Abu-Khalaf M, Wang C, Zhang Z, Luo R, Chong W, Silver DP, Fellin F, Jaslow R, Lopez A, Cescon T, Jiang W, Myers R, Wei Q, Li B, Cristofanilli M, Yang H. Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers (Basel) 2022;14:2872. [PMID: 35740538 DOI: 10.3390/cancers14122872] [Reference Citation Analysis]
4 Mastoraki S, Balgkouranidou I, Tsaroucha E, Klinakis A, Georgoulias V, Lianidou E. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. Mol Oncol 2021;15:2412-22. [PMID: 33159839 DOI: 10.1002/1878-0261.12848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Xiao W, Zhang G, Chen B, Chen X, Wen L, Lai J, Li X, Li M, Liu H, Liu J, Han-Zhang H, Lizaso A, Liao N. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer. Front Oncol 2021;11:618767. [PMID: 33968723 DOI: 10.3389/fonc.2021.618767] [Reference Citation Analysis]
6 Kumar A, Kumari N, Nallabelli N, Prasad R. Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers. Indian J Clin Biochem 2019;34:123-32. [PMID: 31092985 DOI: 10.1007/s12291-019-00828-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:2653. [PMID: 34071259 DOI: 10.3390/cancers13112653] [Reference Citation Analysis]
8 Kanaki Z, Voutsina A, Markou A, Pateras IS, Potaris K, Avgeris M, Makrythanasis P, Athanasiadis EI, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulias V, Kotsakis A, Klinakis A. Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. Cancers (Basel) 2021;13:2446. [PMID: 34070013 DOI: 10.3390/cancers13102446] [Reference Citation Analysis]
9 O'Sullivan B, Seoighe C. vcfView: An Extensible Data Visualization and Quality Assurance Platform for Integrated Somatic Variant Analysis. Cancer Inform 2020;19:1176935120972377. [PMID: 33239857 DOI: 10.1177/1176935120972377] [Reference Citation Analysis]
10 Martinez VG, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, Lodewijk I, Dueñas M, Martínez-Fernández M, Paramio JM. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Front Genet 2019;10:1125. [PMID: 31850055 DOI: 10.3389/fgene.2019.01125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 2020;38:803-817.e4. [PMID: 33157048 DOI: 10.1016/j.ccell.2020.10.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
12 Karakaidos P, Karagiannis D, Rampias T. Resolving DNA Damage: Epigenetic Regulation of DNA Repair. Molecules 2020;25:E2496. [PMID: 32471288 DOI: 10.3390/molecules25112496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Klinakis A, Karagiannis D, Rampias T. Targeting DNA repair in cancer: current state and novel approaches. Cell Mol Life Sci 2020;77:677-703. [PMID: 31612241 DOI: 10.1007/s00018-019-03299-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
14 Porkka NK, Olkinuora A, Kuopio T, Ahtiainen M, Eldfors S, Almusa H, Mecklin JP, Peltomäki P. Does breast carcinoma belong to the Lynch syndrome tumor spectrum? - Somatic mutational profiles vs. ovarian and colorectal carcinomas. Oncotarget 2020;11:1244-56. [PMID: 32292574 DOI: 10.18632/oncotarget.27538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Cimmino F, Lasorsa VA, Vetrella S, Iolascon A, Capasso M. A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma. Front Oncol 2020;10:596191. [PMID: 33381456 DOI: 10.3389/fonc.2020.596191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Okhovat M, Nevonen KA, Davis BA, Michener P, Ward S, Milhaven M, Harshman L, Sohota A, Fernandes JD, Salama SR, O'Neill RJ, Ahituv N, Veeramah KR, Carbone L. Co-option of the lineage-specific LAVA retrotransposon in the gibbon genome. Proc Natl Acad Sci U S A 2020;117:19328-38. [PMID: 32690705 DOI: 10.1073/pnas.2006038117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Klein FG, Granier C, Zhao Y, Pan Q, Tong Z, Gschwend JE, Holm PS, Nawroth R. Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. J Pers Med 2021;11:340. [PMID: 33923231 DOI: 10.3390/jpm11050340] [Reference Citation Analysis]
18 Imran A, Moyer BS, Kalina D, Duncan TM, Moody KJ, Wolfe AJ, Cosgrove MS, Movileanu L. Convergent Alterations of a Protein Hub Produce Divergent Effects within a Binding Site. ACS Chem Biol 2022. [PMID: 35613319 DOI: 10.1021/acschembio.2c00273] [Reference Citation Analysis]
19 Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. J Clin Med 2019;8:E903. [PMID: 31238554 DOI: 10.3390/jcm8060903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 D'Afonseca V, Arencibia AD, Echeverría-Vega A, Cerpa L, Cayún JP, Varela NM, Salazar M, Quiñones LA. Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach. Cancer Inform 2020;19:1176935120922154. [PMID: 32546937 DOI: 10.1177/1176935120922154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Thomas J, Sonpavde G. Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers 2022;14:1795. [DOI: 10.3390/cancers14071795] [Reference Citation Analysis]
22 Chang A, Liu L, Ashby JM, Wu D, Chen Y, O'Neill SS, Huang S, Wang J, Wang G, Cheng D, Tan X, Petty WJ, Pasche BC, Xiang R, Zhang W, Sun P. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer. Cancer Res 2021;81:3358-73. [PMID: 33853832 DOI: 10.1158/0008-5472.CAN-21-0688] [Reference Citation Analysis]
23 Yang L, Jin M, Jeong KW. Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers. Biology (Basel) 2021;10:581. [PMID: 34201935 DOI: 10.3390/biology10070581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Xiong H, Gao H, Hu J, Dai Y, Wang H, Fu M, Qi T, Li L, Xia Q, Jin X, Cui Z, Kang W. Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer. J Oncol 2021;2021:5345181. [PMID: 34354750 DOI: 10.1155/2021/5345181] [Reference Citation Analysis]
25 Poreba E, Lesniewicz K, Durzynska J. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis. Int J Mol Sci 2020;21:E9340. [PMID: 33302406 DOI: 10.3390/ijms21249340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Yang Z, Jiang H. A chromatin perspective on metabolic and genotoxic impacts on hematopoietic stem and progenitor cells. Cell Mol Life Sci 2020;77:4031-47. [PMID: 32318759 DOI: 10.1007/s00018-020-03522-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Machour FE, Abu-Zhayia ER, Awwad SW, Bidany-Mizrahi T, Meinke S, Bishara LA, Heyd F, Aqeilan RI, Ayoub N. RBM6 splicing factor promotes homologous recombination repair of double-strand breaks and modulates sensitivity to chemotherapeutic drugs. Nucleic Acids Res 2021;49:11708-27. [PMID: 34718714 DOI: 10.1093/nar/gkab976] [Reference Citation Analysis]
28 Yang H, Cui W, Wang L. Epigenetic synthetic lethality approaches in cancer therapy. Clin Epigenetics 2019;11:136. [PMID: 31590683 DOI: 10.1186/s13148-019-0734-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Fagan RJ, Dingwall AK. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. Cancer Lett 2019;458:56-65. [PMID: 31128216 DOI: 10.1016/j.canlet.2019.05.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
30 Liu Z, Guo H, Zhu Y, Xia Y, Cui J, Shi K, Fan Y, Shi B, Chen S. TP53 alterations of hormone-naïve prostate cancer in the Chinese population. Prostate Cancer Prostatic Dis 2021;24:482-91. [PMID: 33214693 DOI: 10.1038/s41391-020-00302-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Li B, Ren Q, Li Y, Tian S, Chong Y, Sun S, Feng F. Screening differential circular RNA expression profiles reveals the regulatory role of circMARS in anti-tuberculosis drug-induced liver injury. J Cell Mol Med 2022. [PMID: 35032098 DOI: 10.1111/jcmm.17157] [Reference Citation Analysis]
32 Paraskevopoulou V, Bonis V, Dionellis VS, Paschalidis N, Melissa P, Chavdoula E, Vasilaki E, Pateras IS, Klinakis A. Notch controls urothelial integrity in the mouse bladder. JCI Insight 2020;5:133232. [PMID: 32051338 DOI: 10.1172/jci.insight.133232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Liu X, Qiu R, Xu M, Meng M, Zhao S, Ji J, Yang Y. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. Breast Cancer Res Treat 2021;189:347-61. [PMID: 34240274 DOI: 10.1007/s10549-021-06325-1] [Reference Citation Analysis]
34 Machnicki MM, Rzepakowska A, Janowska J, Pepek M, Krop A, Pruszczyk K, Stawinski P, Rydzanicz M, Grzybowski J, Gornicka B, Wnuk M, Ploski R, Osuch-wojcikiewicz E, Stoklosa T. Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor. Front Oncol 2022;12:768954. [DOI: 10.3389/fonc.2022.768954] [Reference Citation Analysis]
35 Liao C, Hu NX, Song H, Zhang JY, Shen DY, Xu XJ, Tang YM. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. Int J Hematol 2021;113:751-9. [PMID: 33392975 DOI: 10.1007/s12185-020-03070-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Cossío FP, Esteller M, Berdasco M. Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr Opin Chem Biol 2020;57:41-9. [PMID: 32480315 DOI: 10.1016/j.cbpa.2020.04.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
37 Mohan LS, Khan AU, Zhang B, Quan VL, Shi K, Panah E, Isales MC, Yazdan P, Zhang Y, Beaubier N, Taxter TJ, Compres EV, Kim D, White KP, Gerami P. Retrospective Cohort: Genomic Differences Between Pigmented Spindle Cell Nevi of Reed and Reed-Like Melanomas. Am J Dermatopathol 2020;42:641-7. [PMID: 32000215 DOI: 10.1097/DAD.0000000000001603] [Reference Citation Analysis]
38 Sugeedha J, Gautam J, Tyagi S. SET1/MLL family of proteins: functions beyond histone methylation. Epigenetics 2021;16:469-87. [PMID: 32795105 DOI: 10.1080/15592294.2020.1809873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hoffmann MJ, Schulz WA. Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. Cancers (Basel) 2021;13:6040. [PMID: 34885146 DOI: 10.3390/cancers13236040] [Reference Citation Analysis]
40 Lian J, Xu C, Chen X, Huang S, Wu D. Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer. J Cancer Res Clin Oncol 2022. [PMID: 35322299 DOI: 10.1007/s00432-022-03968-5] [Reference Citation Analysis]
41 Wu HT, Liu YE, Hsu KW, Wang YF, Chan YC, Chen Y, Chen DR. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. Am J Chin Med 2020;48:1221-41. [PMID: 32668964 DOI: 10.1142/S0192415X20500603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Meghani K, Folgosa Cooley L, Piunti A, Meeks JJ. Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. BLC 2022. [DOI: 10.3233/blc-211609] [Reference Citation Analysis]
43 Nemtsova MV, Kalinkin AI, Kuznetsova EB, Bure IV, Alekseeva EA, Bykov II, Khorobrykh TV, Mikhaylenko DS, Tanas AS, Strelnikov VV. Mutations in Epigenetic Regulation Genes in Gastric Cancer. Cancers (Basel) 2021;13:4586. [PMID: 34572812 DOI: 10.3390/cancers13184586] [Reference Citation Analysis]
44 Kumar R, Liu APY, Northcott PA. Medulloblastoma genomics in the modern molecular era. Brain Pathol 2020;30:679-90. [PMID: 31799776 DOI: 10.1111/bpa.12804] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
45 Wu Y, Lin H, You X, Guo T, Sun T, Xu H, Fu X. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Front Oncol 2022;12:764923. [DOI: 10.3389/fonc.2022.764923] [Reference Citation Analysis]